Savara presents CHEST 2026 data: Savara stock is valued at USD 978.0 million

Published on 10/15/2026 at 12:56 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Savara will present IMPALA data at CHEST 2026 on October 18-21, 2026. Savara stock costs EUR 4.28 on October 15, 2026, with a USD 12.00 target.

Clinical data and regulatory timing

Savara announced its CHEST 2026 presentations on October 12, 2026.
JPMorgan set a USD 12.00 target on October 7, 2026.
Savara stock was trading at EUR 4.28 at 12:47 p.m. CEST at Lang & Schwarz on October 15, 2026.

SVRA, US8051111016, Illustration mit AI erstellt.

Savara Inc. (ISIN US8051111016) is valued at USD 978.0 million as of October 14, 2026, while its stock was trading at EUR 4.28 at Lang & Schwarz on October 15, 2026 at 12:47 p.m. CEST. According to Business Wire on October 12, 2026, Savara announced accepted presentations of IMPALA trial data at CHEST 2026.

CHEST presentations set for October

The company will present an encore oral session on long-term efficacy and safety data from the Phase 3 IMPALA-2 trial, alongside a poster from the Phase 2/3 IMPALA trial. The event runs from October 18, 2026, through October 21, 2026, in Phoenix, with the oral presentation scheduled for October 20 and the poster session for October 21.

The announcement keeps molgramostim at the center of Savara's clinical story. Business Wire describes the company as a clinical-stage biopharmaceutical developer focused on rare respiratory diseases, with molgramostim in Phase 3 development for autoimmune pulmonary alveolar proteinosis.

Three events shape the setup

Savara announced on July 30, 2026, that European and Australian patent offices had granted protection for the liquid formulation of MOLBREEVI through March 2041. On August 11, 2026, the company reported a second-quarter adjusted loss of USD 0.16 per share, versus a USD 0.14 consensus estimate, according to MarketBeat. On October 12, 2026, Savara announced the CHEST presentations, making the upcoming clinical data the latest dated company event.

What does November add?

The next two dated milestones are the CHEST 2026 presentations from October 18 through October 21, 2026, and Savara's estimated third-quarter results on November 11, 2026. MarketBeat lists the November reporting date after market close and gives a consensus adjusted loss estimate of USD 0.1633 per share.

Analyst expectations provide a separate valuation reference. MarketBeat reported on October 13, 2026, that nine analysts had an average 12-month target of USD 10.25, including JPMorgan's USD 12.00 target and Royal Bank of Canada's USD 10.00 target. The contrast with the second-quarter loss means the clinical readout and regulatory progress remain central to the valuation debate.

Price and upcoming catalysts

Savara stock was trading at EUR 4.28 at Lang & Schwarz on October 15, 2026 at 12:47 p.m. CEST. The euro quotation provides the current German-market perspective, while the October presentations and November reporting date give investors two concrete milestones for assessing the development program.

The further course of trading is shown by the continuously updated real-time quote of SVRA stock.